Last edition
News about "Hansoh Pharma Inc"
Jideytro Wins US Approval for ROS1-Positive NSCLC
Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.
Hansoh Pharma Inc | 24/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members